North Bay Business Journal

Tuesday, August 20, 2013, 4:57 pm

Medtronic reports increased revenues


Print Friendly Print Friendly    

Share this item

    Medtronic, Inc.’s Cardiac and Vascular Group, which includes operations in Santa Rosa, today reported sales of $2.160 billion, an increase of 2 percent, for the first quarter of fiscal year 2014, ended July 26.

    Across the company, Minneapolis-based Medtronic (NYSE:MDT) reported that its first quarter revenues grew by 3 percent across the company, reaching $4.083 billion, for the first quarter, from $4.1 billion.

    The vascular group had “solid growth” after adjusting for foreign currency changes in structural heart, pacing, endovascular, atrial fribulation solution and coronary products, although it was partially offset by a decline in implantable defribillators, which decreased by 2 percent to $655 million in first quarter revenues, according to Medtronic.

    Group international sales of $1.234 billion increased 9 percent after adjusting for changes in currency. Total group revenues reached $1.193 billion, which was flat from the year prior, according to the company.

    Pacing revenue was $474 million, an increase of 6 percent after adjusting for foreign currency. Coronary revenue of $435 million were flat as reported, while sales of drug-eluting stents increased 10 percent on a constant currency basis, driven by continued worldwide share gains of the ResoluteIntegrity drug-eluting stent, Medtronic said.  Structural heart revenue of $313 million grew 12 percent, while endovascular revenue of $219 million grew by 5 percent as reported.

    “Our Q1 results reflect that we are broadly outperforming our sector,” Omar Ishrak, Medtronic chairman and chief executive officer, said in a statement “At the same time, we continue to strengthen and geographically diversify our business and remain confident in both our outlook for the remainder of the year and our long-term competitive position in the changing healthcare environment.”

    Across the company, first quarter net earnings were $953 million, 93 cents per diluted share, an increase of 10 percent and 12 percent from $864 million, or 83 cents per share, respectively, over the same period in the prior year.

    While Medtronic’s earnings kept pace, total revenues fell shy of analysts’ estimates of $4.11 billion. Shares of Medtronic closed at $52.83, down 2.35 percent, and crept back up to $52.85 in after-hours trading.

    In fiscal year 2014, Medtronic said it expects full-year revenue growth in the range of 3 to 4 percent on a constant currency basis, and diluted earnings per share in the range of $3.80 to $3.85.

    “We continue to make progress on our transformational opportunities of globalization and economic value, which we believe will establish durability in our long-term performance and create potential upside to our baseline expectations,” Mr. Ishrak said. “Ultimately, we intend to transform Medtronic from being primarily a device provider today into the premier global medical technology solutions partner of tomorrow.”


    Copyright © 1988–2015 North Bay Business Journal
    View the policy for linking to website content.

    Print Friendly Print Friendly    

    Submit Your Comments


    Required, will not be published

    Comments are moderated and generally will be posted if they are on-topic and not abusive. For more information, please see our Comments and Letters Policy. To share this item by email or social media, use the links above.

    Do not use this form to contact people, companies or organizations mentioned in this story. Contact them directly. Private messages left here will be deleted.